MODIFALS
From zebrafish to man Modifying amyotrophic lateral sclerosis (ALS): translation of biology into therapy
| Coordinatore | VIB
Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie. |
| Nazionalità Coordinatore | Belgium [BE] |
| Totale costo | 2˙467˙990 € |
| EC contributo | 2˙467˙990 € |
| Programma | FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | ERC-2013-ADG |
| Funding Scheme | ERC-AG |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-05-01 - 2019-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
VIB
Organization address
address: Rijvisschestraat 120 contact info |
BE (ZWIJNAARDE - GENT) | hostInstitution | 2˙467˙990.00 |
| 2 |
VIB
Organization address
address: Rijvisschestraat 120 contact info |
BE (ZWIJNAARDE - GENT) | hostInstitution | 2˙467˙990.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of the motor neurons. As for other neurodegenerative disorders, translation of newly acquired biological insights into therapies has been difficult. In the current project we intend to contribute to the development of therapeutic approaches for ALS. We want to generate novel models, identify new therapeutic targets for intervention, and translate these into validated options for drug development in ALS. This will be done by establishing a continuous line of research from the (unbiased) screening for targets in a small animal model (zebrafish), to the exploration of their therapeutic potential, and the validation in patients. In addition, by exploring the significance of some of the findings for other neurodegenerative disorders, we hope to demonstrate this approach to be valid for the field of neurodegenerative disorders in general. This research will be performed bases on 6 work packages (WP): 1.screening of a zebrafish model for ALS to identify therapeutic targets; 2. validation of these targets in larger vertebrate ALS models; 3. investigation of the mechanism of action of these targets in order to establish approaches to interfere with them; 4. validation of these targets in human ALS; 5. generation of preclinical data on these targets; 6. exploration of the possible role of these targets in other neurodegenerative diseases.
Results from WP1 will be used for further research in WP2, results from WP2 in WP3, etc. We have gathered a large set of data in preparatory work in zebrafish, enabling us to start all WPs from the beginning of the project on.
This project involves collaborations with several other groups, national and international, which all have been established. Furthermore, all transgenic mice needed to initiate all these WPs have been generated and available to us.'